Rx Product News

Published Online: Monday, June 16, 2014
Follow Pharmacy_Times:

Marketed by
: kaléo, Inc
Indication: The FDA has approved Evzio (naloxone hydrochloride injection) for emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression. Evzio is for intramuscular or subcutaneous use only. It should be administered to adult or pediatric patients in the anterolateral aspect of the thigh, through clothing if necessary. Emergency medical care should be sought immediately after use. Additional doses may be administered every 2 to 3 minutes until emergency medical assistance arrives.
Dosage Form: Prefilled autoinjector: 0.4 mg/0.4 mL naloxone hydrochloride solution
For More Information: www.evzio.com

Marketed by:
Bayer HealthCare Pharmaceuticals Inc
Indication: Through its service Rosacea Concierge: Your Partner in Rosacea Care, Bayer HealthCare provides 24-hour telephone access to nurses who specialize in rosacea education. This service is designed to assist patients with rosacea, especially those who have received a recent diagnosis. Rosacea Concierge also offers a coupon for Finacea (azelaic acid) gel, 15%, which is indicated for the topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Finacea should be applied to the affected area(s) in a thin layer twice daily.
Dosage Form: Gel: 15%
For More Information: http://rosacea-support.org/rosacea-concierge-from-bayer-healthcare.html; www.myfinacea.com/index.php

Marketed by:
Bristol-Myers Squibb Company; AstraZeneca Pharmaceuticals LP
Indication: Farxiga, a sodium-glucose cotransporter 2 inhibitor, has been FDA approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (DM). Farxiga is not for treatment of type 1 DM or diabetic ketoacidosis. The recommended starting dose is 5 mg once daily, taken in the morning, with or without food. Renal function should be assessed before initiating Farxiga.
Dosage Form: Tablets: 5 and 10 mg
For More Information: www.farxiga-hcp.com

Marketed by:
Bristol-Myers Squibb Company; Pfizer Inc
Indication: The FDA has approved Eliquis (apixaban), a factor Xa inhibitor anticoagulant, to reduce the risk of blood clots following hip or knee replacement surgery. Eliquis is also indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. For prophylaxis of deep vein thrombosis, the recommended dose of Eliquis is 2.5 mg orally twice daily.
Dosage Form: Tablets: 2.5 and 5 mg
For More Information: www.eliquis.com

Related Articles
The introduction of sodium glucose transporter 2 inhibitors has marked a turning point in the management of patients with both type 1 and type 2 diabetes.
It is compulsory for pharmacists to counsel all patients receiving opioids, evaluate the potential benefit of a naloxone reversal device, and contact the opioid prescriber if such a device is deemed appropriate.
The tide of deaths due to unintentional prescription opioid toxicity must be stemmed.
Latest Issues
  • photo
    Pharmacy Times
    Health-System Edition
    Directions in Pharmacy
    OTC Guide
    Generic Supplements
  • photo
    Pharmacy Careers
    Specialty Pharmacy Times